United Therapeutics opened higher at $600.00, compared with its previous close of $593.54. In the last trading session, the stock traded between $593.57 and $609.99. It showed an upward intraday trend.
An investment of $100 made 5 years ago in United Therapeutics is now worth
$ 315.80
giving a profit of
$ 215.80 (215.80%)
Note: Past profits do not guarantee future returns.
Rating from 14 Analysts
Today's Change
+$8.88 (+1.50%)
Day High
$609.99
Day Low
$593.57
Day Open
$600.00
Prev Close
$593.54
Volume
2,04,498
1W Return
2.99%
1M Return
25.17%
3M Return
14.89%
6M Return
5.49%
1Y Return
32.31%
Market Cap ($ Mn)
25,838
PE Ratio
18.46
PB Ratio
3.44
PEG Ratio
0.84
ROE
19.56%
ROCE
21.92%
EPS (TTM)
$7.80
1 Week
2.99%
1 Month
25.17%
3 Months
14.89%
6 Months
5.49%
9 Months
28.80%
United Therapeutics opens third pathogen-free facility in Houston
Opened third Designated Pathogen-Free facility in Houston, Texas. Named after pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. Designed to scale commercial production of xeno-organs post-approval. Advancing clinical trials for UKidney, UThymoKidney, and UHeart products.
10 days agoLeerink Partners raises United Therapeutics price target to $725
Leerink Partners maintains Outperform rating on United Therapeutics. Price target raised from $685 to $725. Analyst Roanna Ruiz authored the rating update.
11 days agoUnited Therapeutics gets FDA clearance for SUMMIT trial in PH-COPD
FDA granted clearance for Phase 2 *SUMMIT* trial of treprostinil SMI in PH-COPD. Study evaluates safety and tolerability in approximately 40 patients over 16 weeks. United Therapeutics plans to begin Phase 3 registration study in 2028 if Phase 2 succeeds. Leadership estimates PH-COPD affects 5 to 10 times more patients than current indications. Treprostinil SMI aims to be the first FDA-approved therapy specifically for PH-COPD.
11 days agoCourt upholds two patent claims against Liquidia's Yutrepia
Court upheld claims 1 and 14 of '327 patent against Liquidia's Yutrepia. United Therapeutics seeks FDA order to withdraw NDA approval for Yutrepia. Potential remedies include market removal or label restriction for PH-ILD.
29 days agoFDA accepts United Therapeutics sNDA for nebulized Tyvaso IPF treatment
FDA accepted sNDA for nebulized Tyvaso to treat idiopathic pulmonary fibrosis. Agency review expected to conclude in late April 2027. Drug would be first inhaled anti-fibrotic for IPF if approved. Treatment remains investigational for this specific indication.
1mo agoUnited Therapeutics to present at four healthcare investor conferences
United Therapeutics executives will present at four investor conferences in September 2026. Martine Rothblatt will speak at all four events; Patrick Poisson joins for one session. Conferences include Wells Fargo, Cantor, Morgan Stanley, and Bernstein forums. Live webcasts and archived recordings will be available on the company website.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 |
An investment of $100 made 5 years ago in United Therapeutics is now worth
$ 315.80
giving a profit of
$ 215.80 (215.80%)
Note: Past profits do not guarantee future returns.
